News and Announcements
Mustang Resources Talks to AFR About Plans for First Ruby Auction as Chinese Market Demand Remains High
- Published July 10, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Emerging ASX-listed company, Mustang Resources have recently featured in the AFR in announcing the company plans to hold the first auction of stones from its Montepuez ruby project in Mozambique, during October 2017. Through low cost, high margin operations, the company intends to generate significant revenue and deliver significant value to shareholders.
KEY TAKEAWAYS:
- Shares in Mustang, trading at 4.3¢ a share, fell from 7.5¢ in April when it suddenly abandoned plans to sell some cut stones, instead opting to sell only rough stones at auction.
- Chinese demand expected to grow, as rubies demonstrate wealth, status and emotional commitment.
Chief Executive, Christiaan Jordaan, said while the potential for Mustang to be a target “sometimes keeps me awake”, the junior had a long way to go before it was a substantial player in the market.
“China is definitely one of the major growth markets that we see coming through,” Mr Jordaan said. “Rubies are very sought after in China due to their religious and cultural significance and it is for that reason Fosun sees value in controlling something like Gemfields.”
Mr Jordaan said he was confident rough auctions would generate better returns and that Mustang’s entry into the market would not hamper prices.
“We are confident there is more than enough room for our supply in an organised sales process that can supply the market and stimulate sizeable growth from where it is today as a $US2 billion per annum industry.”
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
